In a comprehensive in vitro investigation, it was able to suppress the TNF-α-induced canonical NF-κB activation by inhibiting IκBα degradation and NF-κB binding to DNA (98) in KBM-5 (leukemia), MCF-7 (BC), SCC4 (head and neck cancer), H1299 (LC), U937 (lymphoma), U266, RPMI8226 and MM.1S (myeloma) as well as HCT116 (CRC) cells (Table 1). This evidence concerns the gene TNF and leukemia.